Purpose <p>Alzheimer’s disease (AD) is a neurological condition that worsens with time and is identified clinically by behavioural symptoms, cognitive decline, and functional impairment. Dementia is a gradual cognitive impairment affecting everyday functioning, thinking, and memory. It includes a variety of illnesses, the most prevalent of which being AD. This article elaborates on the general characteristics, characterization, and conjugation of dendrimers with medications for the treatment and management of AD.</p> Methods <p>The article then explores several hypotheses for treatment, focusing on current research aimed at developing innovative therapies and strategies using nanotechnology to halt, slow, or potentially cure AD. Among these approaches, dendrimers are highlighted as effective carriers for medications targeting the disease’s characteristic T-tangles and β-amyloid plaques.</p> Results <p>By conjugating with drugs, dendrimers can facilitate their passage across the blood-brain barrier, allowing them to reach the brain. Additionally, dendrimers are described as imaging agents that assist in diagnosing AD and monitoring its progression.</p> Conclusion <p>AD is a complicated illness that involves several physiological components, making conventional therapy techniques typically ineffective. Treatment results are still inadequate despite research efforts, underscoring the disconnect between encouraging discoveries and successful clinical application. With its potential to cure AD and improve cognitive function while reducing the disease’s development, nanotechnology presents a novel avenue to further research efforts.</p> Lay Summary <p>Nanotechnology is a novel technique to further research, offering possible treatment avenues for AD and strategies to increase cognitive function while delaying the advancement of the illness. Treatments based on nanotechnology are urgently needed since they have the potential to enhance therapeutic results.</p> Graphical Abstract <p></p>